EGFR and non-small cell lung carcinoma: Another pan-ErbB inhibitor neratinib was observed promising activity with overall ORR of 60% and mPFS of 9.1 months among NSCLC patients with EGFR exon 18 mutations, suggesting a potential role for neratinib as a systemic treatment option for patients with NSCLC and difficult-to-treat uncommon mutations (Goldman et al., 2021).